QSAR-based models for designing quinazoline/imidazothiazoles/ pyrazolopyrimidines based inhibitors against wild and mutant EGFR

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Chauhan, Jagat Singh ^a   Dhanda, Sandeep Kumar ^a   Singla, Deepak ^a   Agarwal, Subhash M ^b   Raghava, Gajendra P S ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMIDAZOTHIAZOLE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG DETERMINATION; DRUG STRUCTURE; IC 50; INHIBITION KINETICS; MOLECULAR DOCKING; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUPPORT VECTOR MACHINE; VALIDATION PROCESS;

EID: 84903770291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101079     Document Type: Article

References (39)

1. Mao L, Wang Y, Liu Y, Hu X (2004) Molecular determinants for ATP-binding in proteins: a data mining and quantum chemical analysis. J Mol Biol 336: 787-807. (Pubitemid 38183029)
2. Vulpetti A, Bosotti R (2004) Sequence and structural analysis of kinase ATP pocket residues. Farmaco 59: 759-765. (Pubitemid 39335946)
3. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, et al. (2002) Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 38 Suppl 5: S19-27.
4. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
5. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
6. Walker JE, Saraste M, Runswick MJ, Gay NJ (1982) Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1: 945-951.
7. Shibata T, Kawano T, Nagayasu H, Okumura K, Arisue M, et al. (1996) Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol 17: 168-175. (Pubitemid 26151481)
8. Mitsudomi T (2010) Advances in target therapy for lung cancer. Jpn J Clin Oncol 40: 101-106.
9. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167. (Pubitemid 39100331)
10. Raghav D, Sharma V, Agarwal SM (2013) Structural investigation of deleterious non-synonymous SNPs of EGFR gene. Interdiscip Sci 5: 60-68.
11. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, et al. (1996) Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 38: 67-73. (Pubitemid 26031067)
12. Merlo V, Longo M, Novello S, Scagliotti GV (2011) EGFR pathway in advanced non-small cell lung cancer. Front Biosci (Schol Ed) 3: 501-517.
13. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, et al. (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807. (Pubitemid 46606235)
14. Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742-1751.
15. Yun C-H, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227. (Pubitemid 46349842)
16. Du H, Hu Z, Bazzoli A, Zhang Y (2011) Prediction of inhibitory activity of epidermal growth factor receptor inhibitors using grid search-projection pursuit regression method. PLoS One 6: e22367.
17. Pasha FA, Muddassar M, Srivastava AK, Cho SJ (2010) In silico QSAR studies of anilinoquinolines as EGFR inhibitors. J Mol Model 16: 263-277.
18. Singh SK, Dessalew N, Bharatam PV (2006) 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors. Eur J Med Chem 41: 1310-1319. (Pubitemid 44767642)
19. Nandi S, Bagchi MC (2010) 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design. Mol Divers 14: 27-38.
20. Hou T, Zhu L, Chen L, Xu X (2003) Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies. J Chem Inf Comput Sci 43: 273-287.
21. Noolvi MN, Patel HM (2013) A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: A rational approach to anticancer drug design. J Saudi Chem Soc 17: 361-379.
22. Yang S-C, Chang S-S, Chen H-Y, Chen CY-C (2011) Identification of potent EGFR inhibitors from TCM Database@Taiwan. PLoS Comput Biol 7: e1002189.
23. Vema A, Panigrahi SK, Rambabu G, Gopalakrishnan B, Sarma JARP, et al. (2003) Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies. Bioorg Med Chem 11: 4643-4653. (Pubitemid 37194269)
24. Thompson AM, Bridges AJ, Fry DW, Kraker AJ, Denny WA (1995) Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl) amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 38: 3780-3788.
25. Fidanze SD, Erickson SA, Wang GT, Mantei R, Clark RF, et al. (2010) Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorg Med Chem Lett 20: 2452-2455.
26. Hubbard RD, Bamaung NY, Fidanze SD, Erickson SA, Palazzo F, et al. (2009) Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorg Med Chem Lett 19: 1718-1721.
27. Wang GT, Mantei RA, Hubbard RD, Wilsbacher JL, Zhang Q, et al. (2010) Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorg Med Chem Lett 20: 6067-6071.
28. Yap CW (2011) PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 32: 1466-1474.
29. Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272. (Pubitemid 35417619)
30. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
31. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, et al. (2009) The WEKA data mining software. ACM SIGKDD Explor Newsl 11: 10.
32. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, et al. (2009) The WEKA data mining software: an update. SIGKDD Explor 11: 10-18.
33. Joachims T (1999) Making large-scale support vector machine learning practical: 169-184.
34. Chauhan JS, Mishra NK, Raghava GPS (2009) Identification of ATP binding residues of a protein from its primary sequence. BMC Bioinformatics 10: 434.
35. Garg A, Tewari R, Raghava GPS (2010) KiDoQ: using docking based energy scores to develop ligand based model for predicting antibacterials. BMC Bioinformatics 11: 125.
36. Vapnik V (1995) Support-vector networks. Mach Learn 20: 273-297.
37. Platt JC (1998) Sequential Minimal Optimization: A Fast Algorithm for Training Support Vector Machines.
38. Keerthi SS, Shevade SK, Bhattacharyya C, Murthy KRK (2001) Improvements to Platt's SMO Algorithm for SVM Classifier Design. Neural Comput 13: 637-649. (Pubitemid 33595014)
39. Shevade SK, Keerthi SS, Bhattacharyya C, Murthy KK (2000) Improvements to the SMO algorithm for SVM regression. IEEE Trans Neural Netw 11: 1188-1193.